New Crown Outbreak: 59.53 million! Vaccines: AstraZeneta/Oxford UNIVERSITY AZD1222 is 60-90% efficient and supplies to the world without profit!

November 24, 2020 / -- At present, the outbreak of new crown pneumonia abroad is still spreading rapidly.
according to Baidu's Real-Time Big Data Report on the Outbreak of New Coronavirus Pneumonia, as of 12 p.m. on November 24, 2020, there were more than 59.53 million confirmed cases and more than 1.4 million deaths worldwide.
recently, there have been significant breakthroughs in the development of coVID-19 vaccines, including Pfizer/BioNTech's mRNA vaccine BNT162b2 (95 percent efficiency), Moderna's mRNA vaccine mRNA-1273 (94.5 percent efficiency), and AstraZeneta/Oxford University's adenovirus vaccine AZD1222 (60%-90% efficient).
it should be noted that although not as effective as the previous two mRNA vaccines, AZD1222 can be routinely refrigerated (2-8 degrees C), and mRNA vaccines need to be stored and distributed at minus 70 degrees C, with significant limitations.
recently, AstraZeneca announced positive high-level results from mid-clinical trials in the United Kingdom and Brazil to evaluate the COVID-19 vaccine AZD1222.
data show that AZD1222 is very effective in preventing COVID-19 (primary endpoint) and no hospitalization or severe cases have been reported among subjects receiving the vaccine.
in clinical trials, two different immunization regimens showed effectiveness, one of which worked better.
the interim analysis, a total of 131 CASES of COVID-19 were reported.
AZD1222 was co-invented by Oxford University and its spin-off company, Vaccitech.
it uses a weakened version based on the common cold virus (adenovirus) to replicate the defective chimpanzee virus vector, which causes infections in chimpanzees and contains genetic material for the SARS-CoV-2 virus prickly protein.
the vaccine, it produces surface prickly proteins that stimulate the immune system to attack the SARS-CoV-2 virus.
According to AstraZenecom's notification, one of the immunization programmes (n=2741) showed that when AZD1222 was given 1 dose in half dose and 1 dose at least one dose at intervals of at least one month therein, the effectiveness of the vaccine was 90 per cent;
the combined analysis of the two immunization programmes (n-11636) yielded an average effective rate of 70 per cent.
results are statistically significant (p≤0.0001).
data will continue to accumulate and additional analysis will be performed to refine the validity data and determine the duration of protection.
independent Data Security Monitoring Board (DSMB) determined that the analysis reached its main endpoint: the protection of COVID-19 14 days or more after two doses of the vaccine.
no serious vaccine-related safety incidents have been detected.
two immunization programmes, the AZD1222 is well-to-do.
now, AstraZenecom will be ready to submit data to regulators around the world with conditional or early approval frameworks.
the company will seek ways from the World Health Organization to include AZD1222 on its emergency use list to speed up access to vaccines in low-income countries.
, a comprehensive analysis of the interim results will be published in peer-reviewed journals.
, chief executive of AstraZeneta, said: "Today is an important milestone in our fight against the COVID-19 pandemic.
the effectiveness and safety of the vaccine has proven its high effectiveness in preventing COVID-19 and will have a direct impact on this public health emergency.
In addition, the simplicity of the vaccine's supply chain, our unprofitable commitment and our commitment to broad, fair and timely access to vaccines mean that it will be affordable and available globally, with hundreds of millions of doses of vaccines approved.
" summary analysis, including data from the UK COV002 II/III trial and the Brazilian COV003 Phase III trial.
more than 23,000 subjects received two immunization programmes (half-dose/full-dose programme, two full-dose programmes) or a controlled vaccine (meningococcal-binding vaccine MenACWY) or physiological saline, which is currently being evaluated.
these global trials are evaluating healthy or stable subjects aged 18 years or older from different ethnic and geographic groups.
currently being conducted in the United States, Japan, Russia, South Africa, Kenya and Latin America, and are planned in other European and Asian countries.
is expected to have a total of 60,000 subjects worldwide.
AstraZeneta is making rapid progress in production, reaching 300,000 doses by 2021.
AZD1222 vaccine can be stored, transported and treated under normal refrigeration conditions (2-8 degrees Celsius/36-46 degrees Fahrenheit) for at least 6 months and managed in existing medical facilities.
will continue to work with governments, multilateral organizations and partners around the world to ensure widespread and equitable access to non-profit vaccines during the COVID-19 pandemic.
() original source: AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19